208
Participants
Start Date
January 31, 2004
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Escitalopram
Placebo
Peginterferon alfa-2a
Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
Ribavirin
Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
Department of Gastroenterolgy and Rheumatology, Sektion Hepatology, Leipzig
Charite University, Berlin, Germany
OTHER